Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of LB-102 on other drugs

3 evidence topics · 2 sources

Class context: CYP and transporter inhibition by amisulpride

“In vitro, amisulpride did not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, or induce CYP1A2, CYP2C9, CYP2C19, or CYP3A4.” (opens the source at this quote in a new tab)
“Amisulpride inhibits MATE1 and MATE2-K transporters.” (opens the source at this quote in a new tab)
“Amisulpride does not inhibit P-gp, BCRP, OCT1, OCT2, OAT1, OAT3, OATP1B1, OATP1B3 at therapeutic concentrations.” (opens the source at this quote in a new tab)

Class context: pharmacodynamic interactions in amisulpride labeling

“Reciprocal antagonism of effects occurs between dopamine agonists (e.g., levodopa) and BARHEMSYS.” (opens the source at this quote in a new tab)

“Levodopa: reciprocal antagonism of effects between levodopa and neuroleptics.” (opens the source at this quote in a new tab)
“Amisulpride may enhance the central effects of alcohol” (opens the source at this quote in a new tab)
“CNS depressants including narcotics, anaesthetics, analgesics, sedative H1 antihistamines, barbiturates, benzodiazepines and other anxiolytic drugs, clonidine and derivatives” (opens the source at this quote in a new tab)
“Antihypertensive drugs and other hypotensive medications” (opens the source at this quote in a new tab)
“Amisulpride may oppose the effect of dopamine agonists e.g. bromocriptine, ropinirole.” (opens the source at this quote in a new tab)

Class context: drug and disease interactions in amisulpride labeling

“As with other antidopaminergic agents, caution should be also exercised when prescribing Amisulpride to patients with Parkinson's disease since it may cause worsening of the disease.” (opens the source at this quote in a new tab)
“Hyperglycaemia has been reported in patients treated with some atypical antipsychotic agents, including amisulpride, therefore patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on amisulpride, should get appropriate glycaemic monitoring.” (opens the source at this quote in a new tab)

Clinical drug interaction studies with LB-102

No evidence found.

In vitro CYP inhibition, CYP induction, and transporter inhibition by LB-102

No evidence found.